Interestingly, blockade of PD-1/PD-L1, the most commonly used immune checkpoint blockage therapy in the clinic that has achieved resolution of malignancies (265), polarizes macrophage towards an M1-like phenotype (266–268) and increases TAM phagocytic potency against tumor cells (148). Here, PDCD1 is linked to neoplasm.